drugset / Trial / NCT00892203

Efficacy and Safety of BGG492 in the Treatment of Migraine

NCT00892203

Phase 2 Completed 75 enrolled Novartis
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will assess the efficacy and safety of BGG492 used to treat migraine pain.

Timeline

Start
2009-04
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sumatriptan Unknown 100 mg
Subject selurampanel Small molecule 250 mg Oral

Indications